KR102069622B1 - Pharmaceutical composition for prevention or treatment of cancer comprising Lactobacillus fermentum WiKim0102 as active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or treating cancer comprising Lactobacillus fermentum WiKim0102 (accession number: KCCM12356P) isolated from kimchi as an active component. The Lactobacillus fermentum WiKim0102 according to the present invention exhibits excellent anticancer activity, and thus can be usefully used as a composition for use in the treatment, prevention or alleviation of cancer in humans or animals.

Description

Pharmaceutical composition for prevention or treatment of cancer comprising Lactobacillus fermentum WiKim0102 as an active ingredient

The present invention relates to a composition for preventing or treating cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) isolated from kimchi as an active ingredient.

Cancer has the highest mortality rate worldwide, and is the second most common cause of death in Western society after cardiovascular disease. In particular, eating habits are westernized and eating of high-fat diet is common, and colon cancer, breast cancer, and prostate cancer are continuously increasing due to the rapid increase of environmental pollutants and the increase of drinking volume. Lung cancer is increasing due to increased air pollution and air pollution. In this situation, the creation of anti-cancer substances that can contribute to the promotion of human health, the improvement of healthy quality of life and the promotion of human health by enabling early prevention and treatment of cancer are urgently required.

On the other hand, lactic acid bacteria are widely distributed in human and animal oral cavity, intestines, vagina, feces, and fermented foods such as kimchi, and are closely related to human and animal health. Lactic acid bacteria have various health-promoting effects such as intestinal action, harmful bacteria suppression, immunomodulation, blood cholesterol lowering, and anticancer.

Currently, Korean Patent Publication No. 10-2015-0068061 discloses anticancer activity of Lactobacillus plantarum PNU (KCCM11352P) or Lactobacillus mesenteroides PNU (KCCM11353P). 10-1287120 discloses a pharmaceutical composition for treating cancer containing Lactobacillus plantarium DSR CK10 [Accession No .: KFCC-11433P] or Lactobacillus plantarium DSR M2 [Accession No .: KFCC-11432P] as an active ingredient. However, there have been no reports on anticancer activity and superiority with respect to Lactobacillus percentage.

Korean Laid-Open Patent Publication No. 10-2015-0068061 Korean Patent Registration No. 10-1287120

An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising the Lactobacillus pertumtum strain as an active ingredient.

Another object of the present invention is to provide a food composition or food additive composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising the novel kimchi lactic acid bacteria Lactobacillus fermentum strain as an active ingredient.

Another object of the present invention is to provide a feed composition or feed additive composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising the novel kimchi lactic acid bacteria Lactobacillus fermentum strain as an active ingredient.

Accordingly, the present inventors have tried to find a lactic acid bacteria strain showing excellent effects as a probiotic from kimchi and showing the effect of preventing and treating cancer, and as a result, a novel Lactobacillus genus Lactobacillus strain Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102) having anticancer activity ) Was separated and identified to complete the present invention.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. to provide.

The Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102) is a novel strain of Lactobacillus fermentum derived from kimchi. Although the Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102) in the present invention was isolated and identified in kimchi, the access route thereof is not limited thereto.

The Lactobacillus fermentum WiKim0102 of the present invention is a probiotic and has a general intestinal effect and an immune enhancing effect of lactic acid bacteria. It is well known that lactic acid bacteria of the genus Lactobacillus have a formal effect immune enhancing effect.

The present invention also provides a food composition or food additive composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. do.

The present invention also provides a feed composition or feed additive composition for preventing or improving pancreatic cancer, liver cancer, bladder cancer or skin cancer of livestock, including Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. to provide.

Since the Lactobacillus pertumtum WiKim0102 according to the present invention shows excellent anticancer activity, it can be usefully used as a composition for use in the treatment, prevention or improvement of cancer of human or animal.

Figure 1 is a diagram showing a graph treated with Lactobacillus Permanum WiKim0102 in human-derived pancreatic cancer ASPC1 cell line and PANC1 cell line and measured the cell viabiliy assay.
Figure 2 is a diagram showing a graph treated with Lactobacillus Permanum WiKim0102 in a human-derived liver cancer HepG2 cell line and measured the cell viabiliy assay.
Figure 3 is a graph showing the treatment of the Lactobacillus Permanum WiKim0102 in human-derived bladder cancer T24 cell line and measuring the cell viabiliy assay.
Figure 4 is a graph showing the treatment of the cell-derived cancer cell melanoma B16F10 cell line Lactobacillus Permanent WiKim0102 and cell growth rate (cell viabiliy assay).
Figure 5 is a diagram showing a graph of the cell-derived (cell viabiliy assay) treated with Lactobacillus Permanum WiKim0102 in a human-derived normal skin CCD-986-sk cell line.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

According to an embodiment of the present invention, the Lactobacillus fermentum strain isolated from Kimchi has a nucleic acid sequence of SEQ ID NO: 1 (SEQ ID NO: 1) as a result of 16S rRNA sequencing for identification and classification of microorganisms.

Therefore, the microorganism of the present invention having the 16S rRNA sequence of SEQ ID NO: 1 (SEQ ID NO: 1) was named as Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102), dated October 31, 2018 at the Korea Microorganism Conservation Center. Was deposited (Accession No. KCCM12356P).

In the present invention, 'probiotics (probiotics)' is understood as a living microorganism that has a beneficial effect on the health of the host by improving the intestinal microbial environment of the host in the gastrointestinal tract of animals including humans. Probiotics are living microorganisms with probiotic activity that can have a beneficial effect on the intestinal flora of the host when fed in the form of dried cells or fermented products to humans or animals in the form of single or complex strains.

The composition comprising the Lactobacillus fermentum WiKim0102 of the present invention (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient has a prophylactic or therapeutic effect of cancer and can be used as a pharmaceutical composition.

The cancer includes bladder cancer, breast cancer, melanoma, thyroid cancer, parathyroid cancer, rectal cancer, throat, laryngeal cancer, esophageal cancer, pancreatic cancer, stomach cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, gallbladder cancer, oral cancer, colon cancer, near anal cancer, liver cancer, lung cancer and It may be any one cancer selected from the group consisting of colorectal cancer, preferably pancreatic cancer, liver cancer, bladder cancer or skin cancer, but is not limited thereto.

The Lactobacillus pertumtum WiKim0102 included in the composition according to the present invention may exist as live or dead microorganisms and may also exist in a dried or lyophilized form. Forms and formulation methods of lactic acid bacteria suitable for inclusion in various compositions are well known to those skilled in the art.

The composition can be administered orally or parenterally. In the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, pulmonary administration, and rectal administration. It may be administered, but is not limited thereto.

Suitable dosages of the compositions can be prescribed in various ways, such as by the method of formulation, mode of administration, age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion and response to the patient.

When the composition of the present invention is utilized as a pharmaceutical composition, the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and as the adjuvant, excipient, boric Releases, sweeteners, binders, coatings, swelling agents, lubricants, lubricants, flavoring agents, and the like can be used.

The pharmaceutical composition may be preferably formulated into a pharmaceutical composition including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration.

For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, natural and synthetic gums such as natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium benzo Acetate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injection solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

Furthermore, the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be formulated according to each disease or component according to the appropriate method in the art.

The composition comprising the Lactobacillus fermentum WiKim0102 of the present invention (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient may be used as a food composition or food additive composition for preventing or improving cancer.

The food composition may be in the form of a dietary supplement.

The term "health functional food" means a food manufactured and processed using raw materials or ingredients having functional functions useful for the human body according to the law on health functional foods (Article 3 No. 1), and "functionality" means It means to obtain a useful effect for health use such as nutrient control or physiological action on the structure and function of the human body (No. 2).

The food composition may further include food additives, and the suitability as a "food additive", unless otherwise specified, according to the General Regulations of the Food Additives Code and General Test Methods, etc. Judging by the criteria.

Items listed in the "Food Additives Code" include, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, cinnamon acid, natural additives such as color pigments, licorice extract, crystalline cellulose, guar gum, L- Mixed preparations, such as a glutamate sodium preparation, a noodles addition alkali preparation, a preservative preparation, and a tar pigment preparation, are mentioned.

Foods containing the active ingredient of the present invention includes bread, rice cakes, dried fruits, candy, chocolates, chewing gum, confectionery such as ice cream, ice cream products such as ice cream, ice cream powder milk, low fat milk, lactose milk, Processed Milk, Goat Milk, Fermented Milk, Buttered Milk, Concentrated Milk, Milk Cream, Butter Oil, Natural Cheese, Processed Cheese, Milk Powder, Dairy Products such as Whey, Meat Products, Processed Products, Meat Products such as Hamburger, Ham, Fish meat products such as sausages, bacon and other processed meat products, ramen noodles, dried noodles, raw noodles, fried noodles, dehydrated noodles, improved noodles, frozen noodles, pasta noodles, fruit drinks, carbonated drinks, soy milk Lactic acid bacteria beverages such as yogurt, beverages such as mixed drinks, soy sauce, miso, red pepper paste, chunjang, cheonggukjang, mixed soy sauce, vinegar, sauces, tomato ketchup, curry, seasonings such as dressing, margarine, Shortening and pizza, but is not limited thereto.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, It may include a carbonation agent used in the carbonated beverage. In addition, the composition of the present invention may include a pulp for the production of natural fruit juice, fruit juice drinks and vegetable drinks. These components can be used independently or in combination.

The beverage composition including the active ingredient of the present invention is not particularly limited to other ingredients and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the aforementioned natural carbohydrates include monosaccharides (eg, glucose, fructose, and the like); Disaccharides (eg maltose, sucrose and the like); And conventional sugars such as polysaccharides (eg dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have.

In addition, the composition containing the Lactobacillus fermentum WiKim0102 of the present invention (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient may be used as a feed composition or feed additive composition for cancer prevention or improvement in livestock. .

When the composition is prepared as a feed additive, the composition may be 20 to 90% high concentrate or prepared in powder or granule form. The feed additives include organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate and polyphosphate (polyphosphate), polyphenols, catechins, alpha-tocopherols, and rosemary. Extracts, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, such as any one or more of the natural antioxidant may be further included. When prepared as a feed, the composition may be formulated in a conventional feed form and may include conventional feed ingredients together.

The feed and feed additives include grains such as milled or crushed wheat, oats, barley, corn and rice; Vegetable protein feed, such as feed consisting mainly of rapeseed, soybean, and sunflower; Animal protein feeds such as blood meal, meat meal, bone meal and fish meal; Sugars and dairy products, for example, may further include a dry ingredient consisting of various powdered milk and whey powder, and may further include nutritional supplements, digestive and absorption enhancers, growth promoters and the like.

The feed additive may be administered alone or in combination with other feed additives in an edible carrier. In addition, the feed additive may be easily administered to the animal as topdressing or mixed directly with the animal feed or in an oral formulation separate from the feed. When administered separately from the animal feed, the feed additive may be prepared in immediate release or sustained release formulation in combination with a pharmaceutically acceptable edible carrier, as is well known in the art. Such edible carriers may be solid or liquid, for example corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. If a solid carrier is used, the feed additive may be a tablet, capsule, powder, troche or sugar-containing tablet or top dressing in undispersible form. If a liquid carrier is used, the feed additive may be a gelatin soft capsule or a formulation of syrup or suspension, emulsion or solution.

In addition, the feed and feed additives may contain auxiliaries such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters and the like. The feed additive may be used in addition to the feed of the animal by acupuncture, spraying or mixing.

The feed or feed additive of the present invention is applicable to many animal diets, including mammals, poultry and fish.

The mammals can be used not only for pigs, cattle, sheep, goats, experimental rodents, and experimental rodents, but also for pets (eg, dogs, cats), and the like as poultry such as chickens, turkeys, ducks, geese, pheasants, And can also be used for quail, etc., may be used in trout, etc. as the fish, but is not limited thereto.

Example 1. Isolation and Culture of Strains

1-1. Isolation and Identification of Strains

The present inventors isolated lactic acid bacteria from kimchi.

First, the kimchi sample was crushed, and the stock solution of the kimchi extract was plated in MRS agar medium and incubated at 30 ° C. for at least 24 hours. The single colonies formed after the culture were selected by subculture, and the selected single colonies were finally identified through 16S RNA sequencing. Among them, one highly effective lactic acid bacterium was assigned the unique number of WiKim0102 from the World Kimchi Research Institute Microbial Gene Bank and named as Lactobacillus fermentum WiKim0102, and was deposited on October 31, 2018 at the Korea Microbiological Conservation Center. (Accession No. KCCM12356P).

The strain isolated through the embodiment of the present invention, 16S rRNA sequence analysis for the identification of the microorganisms, it was found to have a nucleic acid sequence of SEQ ID NO: 1.

1-2. Cultivation of Strains

A single colony of the Lactobacillus permanum WiKim0102 strain isolated and identified in Example 1-1 was inoculated into 10 ml of MRS liquid medium and shaken at 150 rpm for 16 hours at 37 ° C. After incubation, the cells were centrifuged at 8,000 rpm for 5 minutes to remove the culture solution, and washed three times with PBS (Phosphate Buffered Saline) solution to remove the remaining media components.

Example 2. In vitro anticancer activity efficacy assay

2-1. Preparation of Cell Lines

In order to observe the anticancer activity effect of Lactobacillus fermentum WiKim0102, cell viabiliy assay was measured using Cell counting Kit-8. The cells used in the anticancer activity test were human pancreatic cancer-derived ASPC1, PANC1 cell line, human-derived liver cancer HepG2 cell line, human-derived bladder cancer T24 cell line, mouse-derived skin melanoma B16F10 cell line, and normal skin cell line CCD-986-sk cell line. It was.

Human-derived cancer cells ASPC1, PANC1, HepG2 and T24 cell lines passaged at 5% CO _2, 37 ° C using RPMI medium supplemented with 10% FBS (fetal bovine serum) and 1% penicillin / streptomycin The culture was performed using cells in the growth phase. The cultured ASPC1, PANC1, HepG2 and T24 cells were treated with 0.25% trypsin-EDTA at 37 ° C. for 3 minutes to desorb the cells, washed twice with DPBS, and then prepared as 1 × 10 ⁴ cells / well.

Mouse-derived skin melanoma B16F10 cell line was passaged at 5% CO _{2 at} 37 ° C using DMEM medium supplemented with 10% FBS (fetal bovine serum) and 1% penicillin / streptomycin. Experiment with cells. The cultured B16F10 cells were treated with 0.25% trypsin-EDTA at 37 ° C. for 3 minutes to desorb the cells, washed twice with DPBS, and then prepared as 1 × 10 ⁴ cells / well.

Human-derived normal skin cell CCD-986-sk cell line passaged at 5% CO _2, 37 ° C using RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin The culture was performed using cells in the growth phase. The cultured CCD-986- or cells were treated with 0.25% trypsin-EDTA at 37 ° C. for 3 minutes to desorb the cells, washed twice with DPBS, and then prepared as 1 × 10 ⁴ cells / well.

2-2. Cell viabiliy assay results

The present invention measured the cell viability assay of cells treated with Lactobacillus fermentum WiKim0102 after culturing pancreatic cancer (2 species), liver cancer (1 species), bladder cancer (1 species), skin cancer (1 species). The anti-cancer activity of cancer cells not treated with Lactobacillus pertumtum WiKim0102 was determined based on the growth rate of 100%.

Cell viability assay was treated with MOI1 concentration, followed by incubation for 72 hours, and then absorbance (OD 450 nm) was measured after treatment with Cell counting Kit-8 reagent. The growth rate of the cells treated with Lactobacillus fermentum WiKim0102 was calculated based on the absorbance of the cells that were not treated with Lactobacillus fermentum WiKim0102, and the experimental results are described below. It was.

FIG. 1 shows the results of measuring cell growth rate by treating Lactobacillus permanent WiKim0102 with a human-derived pancreatic cancer ASPC1 cell line and a human-derived pancreatic cancer cell line PANC1.

As shown in FIG. 1, cell growth rates of 26.3% in the human-derived pancreatic cancer ASPC1 cell line and 49.4% in the human-derived pancreatic cancer cell line PANC1 were treated with Lactobacillus fermentum WiKim0102. From the above results, it can be seen that the pancreatic cancer cell line treated with Lactobacillus fermentum WiKim0102 significantly inhibited cell growth rate and thus had excellent anticancer activity efficacy against pancreatic cancer.

In addition, the result of measuring the cell growth rate by treating the human-derived liver cancer HepG2 cell line Lactobacillus percentage WiKim0102 is shown in FIG.

As shown in FIG. 2, the cell growth rate of 31.4% was measured in the human-derived liver cancer HepG2 cell line treated with Lactobacillus permanent WiKim0102. From the results, it can be confirmed that the liver cancer cell line treated with Lactobacillus pertumtum WiKim0102 significantly inhibited cell growth rate and thus had excellent anticancer activity efficacy against liver cancer.

In addition, the result of measuring the cell growth rate by treating the human-derived bladder cancer T24 cell line Lactobacillus Permanum WiKim0102 is shown in FIG.

As shown in FIG. 3, the cell growth rate of 66.8% was measured in the human-derived bladder cancer T24 cell line treated with Lactobacillus permanent WiKim0102. From the above results, it can be seen that the bladder cancer cell line treated with Lactobacillus fermentum WiKim0102 significantly inhibited cell growth and thus had excellent anticancer activity efficacy against bladder cancer.

In addition, the results of measuring the growth rate of the mouse-derived skin melanoma B16F10 cell line treated with Lactobacillus permanent WiKim0102 is shown in FIG.

As shown in FIG. 4, the cell growth rate of 39.7% was measured in the mouse-derived melanoma B16F10 cell line treated with Lactobacillus pertumtum WiKim0102. From the above results, it can be seen that the skin cancer cell line treated with Lactobacillus fermentum WiKim0102 significantly inhibited cell growth and thus had excellent anticancer activity against skin cancer.

In contrast to the above experiment, the result of measuring the cell growth rate by treating the human-derived normal skin CCD-986-sk cell line with Lactobacillus permanent WiKim0102 is shown in FIG. 5.

As shown in FIG. 5, the cell growth rate was measured to be 96.2% in the normal skin cell line treated with Lactobacillus permanum WiKim0102, and it can be seen from the results that Lactobacillus fermentum WiKim0102 is not toxic to normal skin cell lines. .

Korea Microbial Conservation Center (overseas) KCCM12356P 20181031

<110> Korea Food Research Institute <120> Lactobacillus fermentum WiKim0102 having anti-cancer activity and          composition for comprising the same <130> KP181207-03_WiKim0102 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1383 <212> DNA <213> Lactobacillus fermentum <400> 1 cacctgattg attttggtcg ccaacgagtg gcggacgggt gagtaacacg taggtaacct 60 gcccagaagc gggggacaac atttggaaac agatgctaat accgcataac aacgttgttc 120 gcatgaacaa cgcttaaaag atggcttctc gctatcactt ctggatggac ctgcggtgca 180 ttagcttgtt ggtggggtaa ggcctaccaa ggcgatgatg catagccgag ttgagagact 240 gatcggccac aatgggactg agacacggcc catactccta cgggaggcag cagtagggaa 300 tcttccacaa tgggcgcaag cctgatggag caacaccgcg tgagtgaaga agggtttcgg 360 ctcgtaaagc tctgttgtta aagaagaaca cgtatgagag taactgttca tacgttgacg 420 gtatttaacc agaaagtcac ggctaactac gtgccagcag ccgcggtaat acgtaggtgg 480 caagcgttat ccggatttat tgggcgtaaa gagagtgcag gcggttttct aagtctgatg 540 tgaaagcctt cggcttaacc ggagaagtgc atcggaaact ggataacttg agtgcagaag 600 agggtagtgg aactccatgt gtagcggtgg aatgcgtaga tatatggaag aacaccagtg 660 gcgaaggcgg ctacctggtc tgcaactgac gctgagactc gaaagcatgg gtagcgaaca 720 ggattagata ccctggtagt ccatgccgta aacgatgagt gctaggtgtt ggagggtttc 780 cgcccttcag tgccggagct aacgcattaa gcactccgcc tggggagtac gaccgcaagg 840 ttgaaactca aaggaattga cgggggcccg cacaagcggt ggagcatgtg gtttaattcg 900 aagctacgcg aagaacctta ccaggtcttg acatcttgcg ccaaccctag agatagggcg 960 tttccttcgg gaacgcaatg acaggtggtg catggtcgtc gtcagctcgt gtcgtgagat 1020 gttgggttaa gtcccgcaac gagcgcaacc cttgttacta gttgccagca ttaagttggg 1080 cactctagtg agactgccgg tgacaaaccg gaggaaggtg gggacgacgt cagatcatca 1140 tgccccttat gacctgggct acacacgtgc tacaatggac ggtacaacga gtcgcgaact 1200 cgcgagggca agcaaatctc ttaaaaccgt tctcagttcg gactgcaggc tgcaactcgc 1260 ctgcacgaag tcggaatcgc tagtaatcgc ggatcagcat gccgcggtga atacgttccc 1320 gggccttgta cacaccgccc gtcacaccat gagagtttgt aacacccaaa gtcggtgggg 1380 taa 1383

Claims (12)

Pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. The method of claim 1,
The Lactobacillus pertumtum WiKim0102 is a pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer, characterized in that it has a nucleic acid sequence of SEQ ID NO: 1. The method of claim 1,
The composition is a pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer, characterized in that it can be administered by oral administration or parenteral administration. The method of claim 3,
The method of parenteral administration is intravenous administration, pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer. The method of claim 1,
The composition is a pharmaceutical composition for the prevention or treatment of pancreatic cancer, liver cancer, bladder cancer or skin cancer, characterized in that the live bacteria form. Food composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. The method of claim 6,
The food is a health functional food, pancreatic cancer, liver cancer, bladder cancer or skin cancer food composition for prevention or improvement. The method of claim 6,
The food consists of bread, rice cake, candy, chocolate, gum, ice cream, milk, cheese, processed meat products, processed meat products, kimchi, soy sauce, miso, red pepper paste, chunjang, cheonggukjang, vinegar, ketchup, curry, dressing, drink and fermented milk Food composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer, characterized in that any one food selected from the group. Food additive composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient. Feed composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer of domestic animals comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or its culture as an active ingredient. The method of claim 10,
The livestock is any one selected from the group consisting of a pig, a cow, a horse, a sheep, a rabbit, a goat, a rat, a hamster, a guinea pig, a dog, a cat, a chicken, a turkey, a duck, a goose, a pheasant, a quail, a carp, a carp and a trout. That is, feed composition for preventing or improving pancreatic cancer, liver cancer, bladder cancer or skin cancer of the livestock. Feed additive composition for the prevention or improvement of pancreatic cancer, liver cancer, bladder cancer or skin cancer of livestock comprising Lactobacillus fermentum WiKim0102 (Lactobacillus fermentum, WiKim0102, Accession No. KCCM12356P) or a culture thereof as an active ingredient.

Images